FierceBiotech 28 ene 2026 FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling
FierceBiotech 28 ene 2026 'We have an expansive view:' Kardigan CEO knits sharper trials, digital health into cardio strategy
FierceBiotech 27 ene 2026 Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets
FierceBiotech 27 ene 2026 TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio
FierceBiotech 27 ene 2026 'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership
FierceBiotech 27 ene 2026 United Therapeutics' bioengineered temporary liver shows promise in phase 1 trial
FierceBiotech 27 ene 2026 From gene therapies to … firearms? Italian biotech makes unexpected strategic pivot
FierceBiotech 27 ene 2026 After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy
FierceBiotech 27 ene 2026 Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance
FierceBiotech 26 ene 2026 Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial